Abbott Laboratories

113.76-0.7800-0.68%Vol 3.86M1Y Perf -2.09%
May 18th, 2022 14:31 DELAYED
BID113.75 ASK113.77
Open113.42 Previous Close114.54
Pre-Market113.80 After-Market-
 -0.74 -0.65%  - -
Target Price
139.85 
Analyst Rating
Strong Buy 1.29
Potential %
22.48 
Finscreener Ranking
★★+     47.83
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     48.40
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     58.25
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★     45.53
Price Range Ratio 52W %
24.05 
Earnings Rating
Strong Buy
Market Cap199.19B 
Earnings Date
20th Apr 2022
Alpha0.01 Standard Deviation0.06
Beta0.73 

Today's Price Range

112.34114.70

52W Range

104.63142.60

5 Year PE Ratio Range

29.90277.50

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
8.22%
1 Month
-1.50%
3 Months
-1.93%
6 Months
-10.26%
1 Year
-2.09%
3 Years
50.77%
5 Years
166.50%
10 Years
100.40%

TickerPriceChg.Chg.%
ABT113.76-0.7800-0.68
AAPL141.05-8.1889-5.49
GOOG2 266.13-67.9000-2.91
MSFT255.24-10.9600-4.12
XOM90.67-1.4400-1.56
WFC42.24-1.4700-3.36
JNJ177.19-1.6300-0.91
FB194.01-8.6100-4.25
GE75.06-1.3450-1.76
JPM120.35-1.8300-1.50
ValuationValueIndustryS&P 500US Markets
25.50
5.43
4.32
19.70
39.40
5.58
-38 478.70
20.22
201.33B
Forward PE22.48
PEG3.27
Financial StrengthValueIndustryS&P 500US Markets
1.20
1.90
0.33
0.48
18.10
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
57.00
21.50
29.20
14.60
17.41
RevenueValueIndustryS&P 500US Markets
44.51B
25.42
11.63
11.85
DividendsValueIndustryS&P 500US Markets
1.71
1.88
14.58
11.63
Payout ratio45.00
Earnings HistoryEstimateReportedSurprise %
Q01 20221.471.7317.69
Q04 20211.181.3211.86
Q03 20210.921.4052.17
Q02 20211.011.1715.84
Q01 20211.331.32-0.75
Q04 20201.361.456.62
Q03 20200.900.988.89
Q02 20200.430.5732.56
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.113.74Positive
9/2022 QR0.95-13.64Negative
12/2022 FY4.820.00-
12/2023 FY4.88-2.59Negative
Next Report Date-
Estimated EPS Next Report1.47
Estimates Count8
EPS Growth Next 5 Years %7.80
Volume Overview
Volume3.86M
Shares Outstanding1.75M
Shares Float1.71B
Trades Count51.86K
Dollar Volume439.96M
Avg. Volume6.30M
Avg. Weekly Volume7.43M
Avg. Monthly Volume5.84M
Avg. Quarterly Volume5.61M

Abbott Laboratories (NYSE: ABT) stock closed at 114.54 per share at the end of the most recent trading day (a 4.4% change compared to the prior day closing price) with a volume of 8.93M shares and market capitalization of 199.19B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 109000 people. Abbott Laboratories CEO is Robert B. Ford.

The one-year performance of Abbott Laboratories stock is -2.09%, while year-to-date (YTD) performance is -18.62%. ABT stock has a five-year performance of 166.5%. Its 52-week range is between 104.63 and 142.6, which gives ABT stock a 52-week price range ratio of 24.05%

Abbott Laboratories currently has a PE ratio of 25.50, a price-to-book (PB) ratio of 5.43, a price-to-sale (PS) ratio of 4.32, a price to cashflow ratio of 19.70, a PEG ratio of 2.32, a ROA of 10.82%, a ROC of 15.58% and a ROE of 23.03%. The company’s profit margin is 17.41%, its EBITDA margin is 29.20%, and its revenue ttm is $44.51 Billion , which makes it $25.42 revenue per share.

Of the last four earnings reports from Abbott Laboratories, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.47 for the next earnings report. Abbott Laboratories’s next earnings report date is -.

The consensus rating of Wall Street analysts for Abbott Laboratories is Strong Buy (1.29), with a target price of $139.85, which is +22.48% compared to the current price. The earnings rating for Abbott Laboratories stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Abbott Laboratories has a dividend yield of 1.71% with a dividend per share of $1.88 and a payout ratio of 45.00%.

Abbott Laboratories has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.61, ATR14 : 3.40, CCI20 : -2.43, Chaikin Money Flow : -0.03, MACD : -2.46, Money Flow Index : 44.20, ROC : 0.92, RSI : 50.92, STOCH (14,3) : 70.23, STOCH RSI : 1.00, UO : 50.68, Williams %R : -29.77), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Abbott Laboratories in the last 12-months were: Andrea F. Wainer (Option Excercise at a value of $3 369 000), Andrea F. Wainer (Sold 79 456 shares of value $10 535 527 ), Andrew H. Lane (Option Excercise at a value of $5 219 520), Andrew H. Lane (Sold 145 925 shares of value $18 355 280 ), Christopher J. Calamari (Sold 706 shares of value $83 414 ), Daniel Gesua Sive Salvadori (Option Excercise at a value of $4 598 747), Daniel Gesua Sive Salvadori (Sold 118 550 shares of value $16 270 670 ), Daniel J. Starks (Sold 50 000 shares of value $5 661 048 ), Gregory A. Ahlberg (Option Excercise at a value of $2 148 123), Gregory A. Ahlberg (Sold 26 572 shares of value $3 441 337 ), Hubert L. Allen (Sold 1 450 shares of value $171 348 ), Jared L. Watkin (Sold 1 038 shares of value $122 589 ), John F. Ginascol (Option Excercise at a value of $2 148 323), John M. Capek (Option Excercise at a value of $5 227 024), John M. Capek (Sold 149 600 shares of value $20 203 704 ), Joseph J. Manning (Sold 779 shares of value $92 047 ), Julie L. Tyler (Sold 462 shares of value $55 114 ), Lisa D. Earnhardt (Sold 943 shares of value $111 416 ), Louis H. Morrone (Option Excercise at a value of $1 448 508), Louis H. Morrone (Sold 30 621 shares of value $4 098 337 ), Michael D. Dale (Option Excercise at a value of $892 672), Michael D. Dale (Sold 22 653 shares of value $2 710 295 ), Michael J. Pederson (Option Excercise at a value of $1 166 965), Michael J. Pederson (Sold 23 008 shares of value $2 969 173 ), Nancy Mckinstry (Option Excercise at a value of $187 394), Nancy Mckinstry (Sold 1 614 shares of value $187 910 ), Philip P. Boudreau (Sold 8 000 shares of value $1 011 920 ), Randel W. Woodgrift (Option Excercise at a value of $1 104 000), Randel W. Woodgrift (Sold 31 314 shares of value $3 645 102 ), Sammy Karam (Option Excercise at a value of $1 214 400), Sammy Karam (Sold 20 700 shares of value $2 638 023 ), William A. Osborn (Option Excercise at a value of $935 984)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (78.57 %)
11 (78.57 %)
10 (76.92 %)
Moderate Buy
2 (14.29 %)
2 (14.29 %)
2 (15.38 %)
Hold
1 (7.14 %)
1 (7.14 %)
1 (7.69 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.29
Strong Buy
1.29
Strong Buy
1.31

Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

CEO: Robert B. Ford

Telephone: +1 224 667-6100

Address: 100 Abbott Park Road, Abbott Park 60064-6400, IL, US

Number of employees: 109 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

55%45%

Bearish Bullish

56%44%

Bearish Bullish

58%42%

TipRanks News for ABT

Tue, 29 Mar 2022 02:25 GMT Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), CASI Pharmaceuticals (CASI) and Arcus Biosciences (RCUS)

- TipRanks. All rights reserved.

Sun, 06 Mar 2022 11:43 GMT Abbott Labs: More Fuel From COVID-19 to Boost Growth

- TipRanks. All rights reserved.

Fri, 18 Feb 2022 12:37 GMT Abbott Recalls Powder Formulas Manufactured in Michigan Unit

- TipRanks. All rights reserved.

Thu, 27 Jan 2022 16:35 GMT Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Icon (ICLR) and PDS Biotechnology (PDSB)

- TipRanks. All rights reserved.

Wed, 26 Jan 2022 19:55 GMT Abbott Labs (ABT) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Mon, 17 Jan 2022 06:07 GMT Abbott Labs (ABT) Gets a Buy Rating from RBC Capital

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 16:30 GMT Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Becton Dickinson (BDX) and Humana (HUM)

- TipRanks. All rights reserved.

News

Stocktwits